EGFR/PI3K/mTOR inhibitory compounds as well as drugs targeting the Wnt/β-catenin signaling pathways utilized in preclinical and/or clinical investigations for glioma treatment were adapted from [122,123] review papers, respectively (see Figure 3). This evidence concerns the gene PIK3CD and central nervous system cancer.